CONCORDBIO: Q2FY25 revenue rose 18% year-over-year, driven by a 125% increase in formulation sales

About this update from Concord Biotech Ltd.

Q2FY25 saw 18% revenue growth year-over-year, with EBITDA and PAT up 15% and 18% respectively, led by a 125% surge in formulation revenue. Gross margins declined, but strong cash flow and equity growth support ongoing expansion and new product launches.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Concord Biotech Ltd.